Tag: alzheimer disease (AD)

pathology image of a Lewy body inclusion
February 15, 2024/Brain Health

Lewy Body Pathology Linked to Cerebral Amyloid Angiopathy in Alzheimer’s Disease Patients

Recognizing this association aids risk assessment before starting novel immunotherapies

23-NEU-4390509-CQD-Hero-650×450

Microglial Immunometabolism Endophenotypes Implicated in Sex Differences in Alzheimer’s Disease

Study suggests sex-specific pathways show potential for sex-specific therapeutic approaches

23-NEU-3890310-CQD-Hero-650×450

Does Sleep Dysfunction Help Explain Sex Differences in Alzheimer’s Incidence and Progression?

Novel research is comparing sleep measures to biomarkers of neurodegeneration

23-NEU-3739358-CQD-Hero-650×450
April 13, 2023/Brain Health

Markers of Metabolic Syndrome Linked to Cognitive Decline in MCI and Alzheimer’s

High plasma ApoA1 and TG/HDL-C ratio predict faster progression

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-NEU-3482371 Alzheimers-brain-650×450
January 12, 2023/Brain Health

Does Peripheral Inflammation Drive Alzheimer’s Disease Progression?

New research explores the role of immune cell and blood-brain barrier changes

22-NEU-3452010_AI-in-brain-research_650x450

Deep Learning Framework Unveiled for Identifying Risk Genes and Drug Targets in Alzheimer’s Disease

Open-source artificial intelligence technology uses human genetic data to find candidate drugs

22-NEU-3450073-CQD-Hero-650×450
December 13, 2022/Geriatrics

What’s the State of Anti-Amyloid Therapy in the Wake of Initial Clarity AD Findings?

Experts weigh in on the amyloid hypothesis and how to use lecanemab if approved

22-NEU-3383669-CQD-Hero-650×450

Big Patient Data Analyses Pinpoint Telmisartan as a Candidate Drug for Alzheimer’s in Black Adults

Findings underscore need for racial diversity in ongoing and future trials

22-NEU-3275708-CQD-Hero-650×450
October 31, 2022/Brain Health

Alzheimer’s Disease in Women: How Our Understanding Continues to Evolve

Investigative highlights include hormone therapies, biomarkers and early lifestyle interventions

21-NEU-2568466-CQD-Hero-2-650×450

Sildenafil Emerges as a Candidate Drug for Alzheimer’s Disease

69% relative risk reduction in large database analysis prompts plans for mechanistic and phase 2 studies

BackPage 1 of 3Next
Advertisement
Ad